Thinking of joining a study?

Register your interest

Become a volunteer?

NCT04398628 | RECRUITING | Hematologic Disorder

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Sponsor:

American Thrombosis and Hemostasis Network

Brief Summary:

In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well-controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.(1,2,3,4) In 2019 alone, the United States Food and Drug Administration (FDA) has issued approvals for twenty-four new therapies for congenital and acquired hematologic conditions.(5) In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.(6) With this increase in potential new therapies on the horizon, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. ATHN Transcends is a cohort study to determine the safety, effectiveness, and practice of therapies used in the treatment of participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendency. The study consists of 7 cohorts with additional study "arms" and "modules" branching off from the cohorts. The overarching objective of this longitudinal, observational study is to characterize the safety, effectiveness and practice of treatments for all people with congenital and acquired hematologic disorders in the US. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.(7)

Condition or disease

Hematologic Disorder

Bleeding Disorder

Connective Tissue Disorder

Hemophilia

Thrombosis

Von Willebrand Diseases

Thrombophilia

Rare Bleeding Disorder

Platelet Disorder

Factor IX Deficiency

Factor VIII Deficiency

Thalassemia

Sickle Cell Disease

Detailed Description:

This is a longitudinal, natural history observational cohort study being conducted at approximately 150 ATHN-affiliated sites. Participants will be followed for a minimum of 15 years. Harmonized data elements will be collected at the time of enrollment, quarterly, annually, and ad hoc. Base data will be collected for all participants. Specific data will be collected for participants enrolled in cohort-specific Arms and Modules. Each participant will be assigned to a single cohort: Hemophilia, Von Willebrand Disease, Congenital Platelet Disorders, Rare Disorders, Bleeding Not Otherwise Specified (NOS), Thrombosis/Thrombophilia, or Non-Neoplastic Hematologic Conditions. Study Arms and study Modules may be developed to provision disease and/or disease specific insights related to stakeholders, including but not limited to pharmaceutical companies, ATHN, and Hemophilia Treatment Centers (HTCs). Arms may branch off into product-specific data collection via Modules to be collected during the study, in conjunction with planned study assessments. ATHN Transcends Principal Investigators Tammuella Chrisentery-Singleton, MD Ochsner Clinic Foundation American Thrombosis and Hemostasis Network Michael Recht, MD, PhD, MBA Yale University School of Medicine National Bleeding Disorders Foundation PUPs Arm: Principal Investigator: Shannon Carpenter, MD, MS University of Missouri Kansas City School of Medicine Children's Mercy Hospital ALTUVIIO Module: Co-Principal Investigators Shannon Carpenter, MD, MS University of Missouri Kansas City School of Medicine Children's Mercy Hospital Co-Principal Investigator Julie Jaffray, MD University of California San Diego Rady Children's Hospital San Diego INHIBIT Module: Co-Principal Investigators: Nicoletta Machin DO, MS Assistant Professor, Division of Hematology/Oncology Hemophilia Center of Western Pennsylvania University of Pittsburgh Medical Center Hemophilia Natural History Arm: Co-Principal Investigators: Tyler Buckner, MD, MSc Hemophilia and Thrombosis Center University of Colorado Anschutz Medical Campus Michael Recht, MD, PhD, MBA Yale University School of Medicine National Bleeding Disorders Foundation Rebinyn Module Co-Principal Investigators: Lauren Amos, MD Children's Mercy Hospital, Kansas City Guy Young, MD University of Southern California Children's Hospital Los Angeles Hemophilia Gene Therapy Outcomes Arm: Co-Principal Investigators: Janice M. Staber, MD Iowa Hemophilia and Thrombosis Center University of Iowa Stead Family Children's Hospital Ulrike M. Reiss, MD Hemophilia Treatment Center St. Jude's Children's Research Hospital Severe VWD Natural History Arm: Co-Principal Investigators: Robert F. Sidonio, Jr., MD, MSc Aflac Cancer and Blood Disorders Center, Hemophilia of Georgia Center for Bleeding and Clotting Disorders Angela C. Weyand, MD C.S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor Congenital Platelet Disorders Natural History Arm: Principal Investigator Sanjay Ahuja, MD Rainbow Babies \& Children's Hospital, Case Western Reserve University Glanzmann Thrombasthenia Module: Co-Principal Investigators: Divya Citla-Sridhar, MD University of Arkansas for Medical Sciences Arkansas Children's Hospital Meera Chitlur, MD Children's Hospital of Michigan Hemophilia Cohort This cohort includes three Arms and five Modules: Previously Untreated Patients (PUPs) Arm This is a pediatric focused Arm of PUPs with hemophilia A or B. ALTUVIIIO® Module The purpose is to investigate the safety and effectiveness of ALTUVIIIO® in PUPs with hemophilia A. INHIBIT Module This is an observational study assessing inhibitor formation in children with severe hemophilia A. Hemophilia Natural History Arm This Arm is investigating the safety, effectiveness, and practice of treatment for people with hemophilia. Hemlibra® Module All participants treated with Hemlibra® are eligible to participate. Rebinyn® Module The Rebinyn® Module is a prospective study in hemophilia B participants without inhibitors. Hemophilia Gene Therapy Outcomes Arm This Arm is investigating the safety and effectiveness of gene therapy in people with hemophilia. HEMGENIX® Module This is an observational study to characterize the effectiveness and safety of HEMGENIX® in participants with hemophilia B. Congenital Platelet Disorders (CPD) Natural History Arm: The CPD Arm is investigating the safety and efficacy of hemostatic therapies in the prevention or treatment of bleeding events in adult and pediatric participants with inherited congenital platelet disorders. Glanzmann Thrombasthenia (GT) Module: This Module is a study of bleeding symptoms, treatments, and treatment outcomes in patients with Glanzmann thrombasthenia. Von Willebrand Disease Cohort No arms or modules open at this time. Rare Disorders Cohort No arms or modules open at this time. Bleeding NOS No arms or modules open at this time. Thrombosis/Thrombophilia No arms or modules open at this time. Non-Neoplastic Hematologic Conditions No arms or modules open at this time.

Study Type : OBSERVATIONAL
Estimated Enrollment : 3000 participants
Official Title : ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders
Actual Study Start Date : 2020-09-30
Estimated Primary Completion Date : 2035-06
Estimated Study Completion Date : 2035-12

Information not available for Arms and Intervention/treatment

Ages Eligible for Study:
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Participants who meet the following inclusion criteria and none of the exclusion criteria are eligible for enrollment in the base study
  • Inclusion Criteria
    • 1. Any age
    • 2. Having a congenital or acquired non-neoplastic hematologic disorder; or
    • 3. Having a bleeding phenotype as indicated by an age adjusted abnormal ISTH Bleeding Assessment Tool score with an unknown diagnosis; or
    • 4. Connective tissue disorder with bleeding tendency as indicated by an age adjusted abnormal ISTH Bleeding Assessment Tool score.
    Exclusion Criteria
    • 1\. Does not qualify for inclusion in a cohort 2. Unable to give informed consent or assent 3. Unwilling to perform study procedures
    • Cohort Participant Selection
    • Each participant is to be enrolled in the cohort for which they qualify as defined below.
    • Hemophilia Cohort
    • Inclusion Criteria
      • Participants who meet any of the following inclusion criteria are eligible for enrollment into this cohort
        • 1. Factor VIII or factor IX activity \< 50%, without another explanation for low clotting factor other than congenital hemophilia or being a known carrier for congenital hemophilia; OR
        • 2. Being a known carrier for congenital hemophilia with a factor VIII or factor IX activity greater than or equal to 50% with or without a bleeding phenotype as indicated by an age-adjusted abnormal ISTH Bleeding Assessment Tool score; OR
        • 3. Known congenital hemophilia that have a factor level \>50% after receiving vector; OR
        • 4. Acquired hemophilia
        Exclusion Criteria
        • None
        • Von Willebrand Disease Cohort
        • Inclusion Criteria
          • Participants who meet the following inclusion criteria are eligible for enrollment into this cohort
            • 1\. Meeting the definition of VWD or low VWF per most recent international guidelines
            Exclusion Criteria
            • None
            • Congenital Platelet Disorders Cohort
            • Inclusion Criteria
              • Participants who meet the following inclusion criteria are eligible for enrollment into this cohort
                • 1. Abnormalities of platelet function
                • 1. Glanzmann thrombasthenia (GPIIb or GPIIIa)
                • 2. Bernard-Soulier syndrome (GPIbalpha, GPIbbeta, or GPIX)
                • 2. Abnormalities of platelet granules
                • 3. Abnormalities of platelet signal transduction
                • 4. Abnormalities of platelet secretion
                • 5. Collagen Receptor Defect
                • 6. ADP Receptor Defect
                • 7. Thromboxane Receptor Defect
                • 8. Giant Platelet Disorder
                • 9. Abnormalities in platelet aggregation testing due to another or unknown cause (not drug related)
                Exclusion Criteria
                • Platelet disorders secondary to medications or other substances
                • Rare Disorders Cohort
                • Inclusion Criteria
                  • Participants who meet the following inclusion criteria are eligible for enrollment into this cohort
                    • 1\. Have an established Rare Coagulation Disorder (RCD) diagnosis of one of the following
                      • 1. PAI-1 deficiency
                      • 2. Factor I, II, V, VII, X, XI, XIII deficiencies
                      • 3. Combined FV and FVIII deficiency
                      • 4. Plasminogen deficiency
                      • 5. Decreased tissue plasminogen activator
                      • 6. Afibrinogenemia/hypofibrinogenemia/dysfibrinogenemia
                      Exclusion Criteria
                      • None
                      • Bleeding NOS Cohort
                      • Inclusion Criteria
                        • Participants who meet the following inclusion criteria are eligible for enrollment into this cohort
                          • 1. Have a bleeding phenotype as indicated by an age-adjusted abnormal ISTH Bleeding Assessment Tool score with an unknown diagnosis; OR
                          • 2. Connective tissue disorder with bleeding tendency as indicated by an age-adjusted abnormal ISTH Bleeding Assessment Tool score
                          Exclusion Criteria
                          • None
                          • Thrombosis/Thrombophilia Cohort
                          • Inclusion Criteria
                          • Participants who meet the following inclusion criteria are eligible for enrollment into this cohort
                            • 1. Have a prior history of arterial or venous thrombosis
                            • 2. Patients with a known congenital or acquired thrombophilia with or without a thrombosis a. Common congenital thrombophilias:: i. Protein C deficiency ii. Protein S deficiency iii. Antithrombin deficiency iv. Factor V Leiden v. Prothrombin gene mutation b. Rare genetic factors i. Hyperhomocysteinemia c. Indeterminate genetic factors i. Elevated factor VIII ii. Elevated factor IX iii. Elevated factor XI iv. Elevated lipoprotein (a) d. Acquired thrombophilias i. Lupus anticoagulant ii. Anti-cardiolipin antibodies/Beta2 glycoprotein antibodies iii. Antiphospholipid syndrome
                            Exclusion Criteria
                          • 1\. Acquired thrombophilia secondary to medications (birth control pills or hormone replacement therapy, overweight or obesity, smoking, cancer, pregnancy, surgery, injury, prolonged inactivity/bedrest, heart failure, inflammatory bowel disease, or kidney disease
                          • Non-Neoplastic Hematologic Conditions Cohort
                          • Inclusion Criteria
                          • Participants who meet the following inclusion criteria are eligible for enrollment into this cohort
                            • 1\. Having any congenital or acquired non-neoplastic hematologic disorder not included in any other cohort
                            Exclusion Criteria
                          • None
                          • Previously Untreated Patients Arm Eligibility Criteria
                          • Inclusion Criteria Diagnosis of congenital hemophilia A (FVIII \<40%) or hemophilia B (FIX \<40% or below lower limit for age)
                          • 1. Age \<18 years at time of enrollment
                          • 2. Parent or authorized guardian or legally authorized representative (LAR) can provide informed consent
                          • 3. Care established at one of the participating HTCs
                          Exclusion Criteria
                        • 1. CFC exposure, fresh frozen plasma (FFP), cryoprecipitate, and single donor platelets \>3 EDs
                        • 2. Concomitant diagnosis with another bleeding disorder
                        • 3. History of confirmed inhibitor
                        • INHIBIT Module Eligibility Criteria
                          • Inclusion Criteria
                          • 1. Diagnosis of severe factor VIII deficiency with baseline factor VIII level \<1%
                          • 2. Initiating or plan to initiate prophylaxis with emicizumab or factor replacement
                          • 3. Factor exposure, plasma/FFP, cryo, and single donor platelets ≤3 EDs
                          • 4. ≤5 years of age
                          Exclusion Criteria
                        • 1. Concomitant diagnosis with bleeding disorder other than hemophilia A
                        • 2. Immune disorder
                        • 3. Factor exposure, plasma/FFP, cryo, and single donor platelets \>3 EDs
                        • 4. Previous history or presence of factor VIII inhibitor
                        • ALTUVIIIO® Module Eligibility Criteria
                          • Inclusion criteria
                            • * People with severe HA with a baseline FVIII activity of less than 1%. (While inclusion for participation in ATHN Transcends lists \<5% FVIII activity, this proposed module will limit enrollment to people with FVIII activity levels of \<1%)
                            • * \<18 years of age
                            • * No history of FVIII inhibitor
                            • * Sex at birth of male, female, or intersex
                            • * Participants may be exposed to unfractionated blood components, no more than one dose of FVIII concentrate other than efanesoctocog alfa and up to three doses of efanesoctocog alfa prior to enrollment
                            • * Potential participants who have a history of bleeding will be eligible for participation if they meet all other inclusion criteria
                            • Exclusion criteria
                              • * Not meeting all the inclusion criteria
                              • * Any exposure to blood components or FVIII replacement products except as described in the inclusion criteria
                              • * History of positive inhibitor testing
                              • * History of hypersensitivity reactions associated with efanesoctocog alfa administration
                              • * Any concurrent clinically significant major disease that, in the investigator's opinion, would make the participant unsuitable for enrollment.
                              • * The presence of any additional inherited bleeding disorder diagnosis
                              • * Enrollment in a concurrent clinical interventional drug study
                              • * Intake of an Investigational Medicinal Product within three months prior to inclusion in this study
                              • * Inability to comply with study requirements
                              • * Other, unspecified reasons that, in the investigator's opinion, make the participant unsuitable for enrollment.
                              • Hemophilia Natural History Arm Eligibility Criteria
                                • Inclusion Criteria
                                • 1\. Congenital hemophilia A or B of any severity with or without inhibitors receiving a current therapy, a non-factor product, or for whom use of a non-factor product is a possibility.
                                Exclusion Criteria
                              • 1. Presence of any known bleeding disorder other than congenital hemophilia A or B
                              • 2. Presence of concurrent hemophilia and a second hemostatic defect (low Von Willebrand Factor (VWF) without VWD diagnosis is not excluded)
                              • 3. Unable or unwilling to comply with the study arm protocol.
                              • Rebinyn® Module Eligibility Criteria
                              • Inclusion Criteria
                                • Participants who meet the following inclusion criteria at the time of screening are eligible to enroll in the study module.
                                • Rebinyn® Cohort
                                • 1. Has provided signed written consent for the Rebinyn® Module before any study-related activities.
                                • 2. Male participants, at any age with hemophilia B, naïve or minimally exposed (up to 3 EDs) to nonacog beta pegol treatment at time of study enrollment.
                                • 3. Decision to initiate treatment with commercially available nonacog beta pegol has been made by the participant(s)/Legally Authorized Representative(s) (LAR(s)) and the treating physician before and independently from the decision to include the participant in this study.
                                • Rebinyn® RWE Cohort
                                • 1. Has provided signed written consent for ATHN Transcends Study before any study-related activities.
                                • 2. Currently treated with nonacog beta pegol
                                • 3. Any age
                                Exclusion Criteria
                                • Participants who fall into any of the following exclusion criteria at the time of screening are not eligible for enrollment into the study module
                                  • Rebinyn® Cohort
                                  • 1. Previous participation in this study. Participation is defined as having given informed consent in this study.
                                  • 2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation, including a diagnosis or suspicion of attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) per the discretion of the Principal Investigator.
                                  • 3. Known or suspected hypersensitivity to nonacog beta pegol or related products.
                                  • 4. Clinical suspicion or presence of FIX inhibitor at time of inclusion.
                                  • 5. Inability or unwillingness to undergo the neurological assessment/ structured developmental history.
                                  • Rebinyn® RWE Cohort 1. None
                                  • Hemophilia Gene Therapy Outcomes Arm Eligibility Criteria
                                    • Inclusion Criteria
                                    • 1. Hemophilia A or B of any severity with or without inhibitors having received or will receive a hemophilia gene transfer product in the next 6 months.
                                    • 2. Age 18 years and older
                                    • 3. Able to give informed consent.
                                    • Exclusion Criteria None
                                    • HEMGENIX® Module Eligibility Criteria
                                    • Inclusion Criteria
                                      • HEMGENIX Cohort • Age 18 years of age or older
                                      • • Treatment with commercial HEMGENIX
                                      • • Have provided signed written informed consent within 3 months before or within 6 months after HEMGENIX treatment, or within 6 months of when the study is initiated at the treating site.
                                      • Exclusion Criteria, both cohorts
                                        • • Have been treated with etranacogene dezaparvovec in a clinical trial.
                                        • Congenital Platelet Disorders Arm Eligibility Criteria
                                          • Inclusion Criteria
                                          • 1. Platelet adhesion defect
                                          • 1. Bernard Soulier syndrome (Defective GPIb-IX-V receptor, impaired adhesion to VWF)
                                          • 2. Velocardio-facial syndrome/DiGeorge syndrome (Defective GPIb-IX-V receptor)
                                          • 3. Platelet type vWD (Defective GPIb-IX-V, gain of function interaction between VWF-GP1bα)
                                          • 2. Platelet aggregation defect
                                          • 1. Glanzmann thrombasthenia (Defective integrin αIIbβ3 (GPIIb/IIIa)
                                          • 2. Platelet aggregation defect, NOS
                                          • 3. Agonist receptor defects
                                          • 1. Epinephrine
                                          • 2. ADP
                                          • 3. Collagen
                                          • 4. Thromboxane A2
                                          • 4. Platelet signaling defects
                                          • 1. Cyclooxygenase deficiency (PTGS1 mutation)
                                          • 2. Phospholipase A2 deficiency
                                          • 3. Thromboxane synthase deficiency (TBXAS1 mutation)
                                          • 4. G protein activation defect (GNAS mutation)
                                          • 5. Scott syndrome (defect in phosphatidyl serine translocation)
                                          • 5. Platelet Granule disorders
                                          • 1. Dense granule storage pool disorder • Hermansky Pudlak syndrome
                                          • * Chediak Higashi syndrome
                                          • * Griscelli syndrome
                                          • 2. Alpha granule storage pool disorder
                                          • • Grey platelet syndrome
                                          • * Arthrogryposis-Renal Dysfunction-Cholestasis (ARC) syndrome
                                          • * Quebec platelet disorder
                                          • * Paris-Trousseau syndrome
                                          • 3. Combined alpha delta granule deficiency
                                          • 6. Platelet cytoskeletal structure defects
                                          • 1. Wiskott Aldrich syndrome
                                          • 2. MYH9 associated disorders (myosin heavy chain)
                                          • • May Hegglin syndrome
                                          • • Fechtner syndrome
                                          • * Sebastian syndrome
                                          • * Epstein syndrome
                                          • 3. Other mutations • FLNA mutations (Filamin) • DIAPH1 (Actin and microtubules) • ACTN1 (alpha actinin) • TPM4 (tropomyosin)
                                          • * TUBB1 (beta tubulin)
                                          • 7. Other Congenital thrombocytopenias
                                          • 1. Familial platelet disorders and predisposition to AML (RUNX1)
                                          • 2. X linked thrombocytopenia with dyserythropoiesis (GATA1)
                                          • 3. Congenital amegakaryocytic thrombocytopenia (MPL)
                                          Exclusion Criteria
                                        • 1. Diagnosis of von Willebrand disease (Meeting the definition of VWD or low VWF per most recent international guidelines)
                                        • 2. Diagnosis of Hemophilia A or Hemophilia B (Factor VIII or IX ≤ 40%)
                                        • FIX Prophylaxis Cohort
                                        • • Age 18 years of age or older
                                        • • Treatment with FIX prophylaxis therapy
                                        • • Has provided signed written consent at any time for ATHN Transcends Study
                                        • Glanzmann Thrombasthenia (GT) Module Eligibility Criteria
                                          • Inclusion Criteria
                                          • 1\. Participant has signed the informed consent/assent form 2. Participant has flow cytometry or aggregometry or genetics confirmed GT 3. Participant is willing to perform study procedures, including daily bleed tracking for 3 months
                                          Exclusion Criteria None
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Location Details

NCT04398628

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Arizona

Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital

Phoenix, Arizona, United States, 85016

RECRUITING

United States, Arkansas

Arkansas Center for Bleeding Disorders

Little Rock, Arkansa, United States, 72202

RECRUITING

United States, California

Orthopaedic Institute for Children HTC

Los Angeles, California, United States, 90007

RECRUITING

United States, California

Childrens Hospital Los Angeles

Los Angeles, California, United States, 90027-6016

RECRUITING

United States, California

UCSF Benioff Children's Hospital Oakland

Oakland, California, United States, 94610

RECRUITING

United States, California

University of California at Davis Hemophilia Treatment Center

Sacramento, California, United States, 95817

RECRUITING

United States, California

Loma Linda Hemoglobinopathy and Inherited Bleeding Disorder Program

San Bernardino, California, United States, 92408

RECRUITING

United States, California

Hemophilia & Thrombosis Treatment Center at UC San Diego Health

San Diego, California, United States, 92121

RECRUITING

United States, California

Rady Children's Hospital San Diego

San Diego, California, United States, 92123

RECRUITING

United States, California

University of California, San Francisco Hemophilia & Thrombosis Center

San Francisco, California, United States, 94143

RECRUITING

United States, Colorado

University of Colorado Denver Hemophilia and Thrombosis Center

Aurora, Colorado, United States, 80045

RECRUITING

United States, Connecticut

Connecticut Children's Medical Center

Hartford, Connecticut, United States, 06106

RECRUITING

United States, Connecticut

Yale Hemophilia Treatment Center

New Haven, Connecticut, United States, 06520

RECRUITING

United States, Delaware

Delaware Hemophilia Treatment Center

Wilmington, Delaware, United States, 19801

RECRUITING

United States, District of Columbia

Georgetown University

Washington D.C., District of Columbia, United States, 20007

RECRUITING

United States, District of Columbia

Children's National Hemophilia Center

Washington D.C., District of Columbia, United States, 20010

RECRUITING

United States, Florida

University of Florida Hemophilia Treatment Center

Gainesville, Florida, United States, 32610

RECRUITING

United States, Florida

University of Miami Comprehensive Hemophilia Treatment Center

Miami, Florida, United States, 33136

NOT YET RECRUITING

United States, Florida

Arnold Palmer Hospital for Children - The Haley Center for Children's Cancer and Blood Disorders

Orlando, Florida, United States, 32806

RECRUITING

United States, Florida

Johns Hopkins All Children's Hospital

St. Petersburg, Florida, United States, 33701

RECRUITING

United States, Florida

St. Joseph's Hospital Center for Bleeding & Clotting Disorders

Tampa, Florida, United States, 33607

RECRUITING

United States, Georgia

Comprehensive Bleeding Disorders Center at Emory University and Children's Healthcare of Atlanta

Atlanta, Georgia, United States, 30308

RECRUITING

United States, Georgia

Emory/Children's Health Care of Atlanta

Atlanta, Georgia, United States, 30322

RECRUITING

United States, Georgia

Memorial Health University Medical Center

Savannah, Georgia, United States, 31403

RECRUITING

United States, Illinois

Rush University Medical Center

Chicago, Illinois, United States, 60612

RECRUITING

United States, Illinois

Bleeding and Clotting Disorders Institute

Peoria, Illinois, United States, 61664

RECRUITING

United States, Indiana

Indiana Hemophilia and Thrombosis Center

Indianapolis, Indiana, United States, 46260

RECRUITING

United States, Iowa

Iowa Hemophilia and Thrombosis Center

Iowa City, Iowa, United States, 52242

RECRUITING

United States, Louisiana

Louisiana Center for Bleeding and Clotting Disorders, Tulane University

New Orleans, Louisiana, United States, 70112

RECRUITING

United States, Maine

Maine Hemophilia and Thrombosis Center

Scarborough, Maine, United States, 04074

RECRUITING

United States, Maryland

Johns Hopkins University Hemophilia Treatment Center

Baltimore, Maryland, United States, 21287

NOT YET RECRUITING

United States, Massachusetts

Massachusetts General Hospital Comprehensive Hemophilia and Thrombosis Treatment Center

Boston, Massachusetts, United States, 02114

RECRUITING

United States, road cancer

Central Michigan Children's Hospital of Michigan

Detroit, road cancer, United States, 48201

RECRUITING

United States, road cancer

Henry Ford Health System Bleeding and Thrombosis Treatment Center

Detroit, road cancer, United States, 48202

RECRUITING

United States, Minnesota

Mayo Comprehensive Hemophilia Center

Rochester, Minnesota, United States, 55905

RECRUITING

United States, Missouri

Children's Mercy Hospital - Kansas City

Kansas City, Missouri, United States, 64108

RECRUITING

United States, Missouri

The John Bouhasin Center for Children with Bleeding Disorders

St Louis, Missouri, United States, 63104

RECRUITING

United States, Nevada

Cure 4 The Kids Foundation

vegas, Nevada, United States, 89135

RECRUITING

United States, Nevada

Hemostasis and Thrombosis Center of Nevada

Reno, Nevada, United States, 89509

RECRUITING

United States, New Jersey

Newark Beth Israel Medical Center - Hemophilia Center

Newark, New Jersey, United States, 07122

RECRUITING

United States, New Mexico

University of New Mexico Ted R. Montoya Hemophilia & Thrombosis Program

Albuquerque, New Mexico, United States, 87131

RECRUITING

United States, New York

Western New York BloodCare

Buffalo, New York, United States, 14202

RECRUITING

United States, New York

Northwell Health Hemostasis and Thrombosis Center at Long Island Jewish and Cohen Children's Medical Center

Hyde Park, New York, United States, 11040

RECRUITING

United States, New York

Weill Cornell Medical College - New York Presbyterian Hospital

New York, New York, United States, 10065

RECRUITING

United States, New York

American Thrombosis and Hemostasis Network

Rochester, New York, United States, 14626

RECRUITING

United States, New York

Montefiore Medical Center

The Bronx, New York, United States, 10461

RECRUITING

United States, North Carolina

Comprehensive Hemophilia Treatment Center, University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States, 27517

RECRUITING

United States, North Carolina

St. Jude Affiliate Clinic at Novant Health Hemby Children's Hospital

Charlotte, North Carolina, United States, 28204

RECRUITING

United States, North Carolina

East Carolina University Hemophilia Treatment Center

Greenville, North Carolina, United States, 27834

RECRUITING

United States, North Carolina

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States, 27157

RECRUITING

United States, Ohio

Akron Children's Hospital - Showers Center for Cancer & Blood Disorders

Akron, Ohio, United States, 44308

RECRUITING

United States, Ohio

Cincinnati Children's Hospital Medical Center, Hemophilia & Thrombosis Center

Cincinnati, Ohio, United States, 45229

RECRUITING

United States, Ohio

University of Cincinnati Medical Center Hemophilia Treatment Center

Cincinnati, Ohio, United States, 45267

RECRUITING

United States, Ohio

University Hospitals Health System Cleveland

Cleveland, Ohio, United States, 44106

RECRUITING

United States, Ohio

Nationwide Children's Hospital Columbus

Columbus, Ohio, United States, 43205

RECRUITING

United States, Ohio

Dayton Children's Hemostasis and Thrombosis Center

Dayton, Ohio, United States, 45404

RECRUITING

United States, Ohio

Northwest Ohio Hemophilia Treatment Center at the Toledo Hospital

Toledo, Ohio, United States, 43606

RECRUITING

United States, Pennsylvania

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

RECRUITING

United States, Pennsylvania

Penn Comprehensive Hemophilia and Thrombophilia Program/Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

RECRUITING

United States, Pennsylvania

Hemophilia Center of Western Pennsylvania

Pittsburgh, Pennsylvania, United States, 15213

RECRUITING

United States, Rhode Island

Rhode Island Hospital Hemostasis and Thrombosis Center

Providence, Rhode Island, United States, 02903

RECRUITING

United States, Tennessee

St. Jude Children's Research Hospital

Memphis, Tennessee, United States, 38105

RECRUITING

United States, Tennessee

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37212

RECRUITING

United States, Texas

Children's Blood and Cancer Center of Central Texas

Austin, Texas, United States, 78723

RECRUITING

United States, Texas

North Texas Hemophilia and Thrombosis Program - Pediatric Program / Center for Cancer & Blood Disorders

dallas, Texas, United States, 75235

RECRUITING

United States, Texas

North Texas Comprehensive Hemophilia Treatment Center

dallas, Texas, United States, 75390

RECRUITING

United States, Texas

Fort Worth Bleeding Disorders Program

Fort Worth, Texas, United States, 76104

RECRUITING

United States, Texas

Gulf States Hemophilia and Thrombophilia Center

Houston, Texas, United States, 77030

RECRUITING

United States, Texas

Texas Children's Hemophilia & Thrombosis Center/Baylor College of Medicine

Houston, Texas, United States, 77030

RECRUITING

United States, Texas

South Texas Comprehensive Hemophilia and Thrombophilia Treatment Center

Saint Anthony, Texas, United States, 78229

RECRUITING

United States, Washington

Washington Center for Bleeding Disorders

Seattle, Washington, United States, 98101

RECRUITING

United States, Wisconsin

Hemophilia Outreach Center Green Bay

Green Bay, Wisconsin, United States, 54311

RECRUITING

United States, Wisconsin

Comprehensive Center for Bleeding Disorders

Milwaukee, Wisconsin, United States, 53226